Ad Boards

DeciBio conducted 12 interviews with U.S. clinicians and healthcare professionals to understand how blood-based EDx testing is being clinically adopted, to identify key regulatory and commercial barriers to broader use, to define the excitement around single and multi-cancer early detection (MCED) tests, and to collect vendor feedback from current users.

DeciBio conducted 9 interviews with experts at top Academic Medical Centers (AMC) and top biopharma stakeholders to better understand their perceptions and use of real-world data (RWD) at their organizations, as well as key RWD unmet needs and vendor perceptions.

DecBio conducted 10 interviews with clinical oncologists and KOLs at top biopharma to better understand their definitions and use of comprehensive genomic profiling (CGP) in the diagnosis and treatment of solid tumors, as well as key CGP pain points and vendor perceptions.

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.

DeciBio conducted 10 interviews with stakeholders at pharmaceutical companies to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DecBio conducted 10 interviews with KOLs at academic medical centers, pharmaceutical companies, reference labs, and CROs to better understand their perception of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS.

DeciBio conducted 11 interviews with KOLs at pharmaceutical companies to understand how pharma spends their money in support of therapeutic / precision medicine development initiatives today, and how these investments may change in the future

DeciBio conducted 10 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools have been adopted into research efforts today

DeciBio conducted 10 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care